A Randomized, Double-blind, Placebo-controlled Trial of the Efficacy and Safety of DEB025/Alisporivir in Combination With Peg-IFNα2a and Ribavirin in Hepatitis C Genotype 1 Treatment-naïve Patients
Phase of Trial: Phase III
Latest Information Update: 04 Oct 2016
At a glance
- Drugs Alisporivir (Primary) ; Peginterferon alfa-2a; Ribavirin
- Indications Hepatitis C
- Focus Registrational; Therapeutic Use
- Sponsors Novartis
- 01 Aug 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 16 Aug 2012 Planned End Date changed from 1 Aug 2014 to 1 Nov 2013 as reported by ClinicalTrials.gov.
- 28 Jul 2012 Additional location (Turkey) added as reported by European Clinical Trials Database.